{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:22:50Z","timestamp":1775283770379,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ygyno.2013.05.025","type":"journal-article","created":{"date-parts":[[2013,5,26]],"date-time":"2013-05-26T09:46:25Z","timestamp":1369561585000},"page":"615-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["The effect of statins on risk and survival of gynecological malignancies"],"prefix":"10.1016","volume":"130","author":[{"given":"Ofer","family":"Lavie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Pinchev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedy S.","family":"Rennert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakir","family":"Segev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gad","family":"Rennert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.05.025_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0010","first-page":"w13310","article-title":"Statins in clinical medicine","volume":"141","author":"Rutishauser","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0015","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients","volume":"25","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0020","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0025","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1378\/chest.06-0931","article-title":"Statins reduce the risk of lung cancer in humans: a large case\u2013control study of US veterans","volume":"131","author":"Khurana","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/ajg.2010.475","article-title":"Statin use and the risk of liver cancer: a population-based case\u2013control study","volume":"106","author":"Chiu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CEJ.0b013e3282b721fe","article-title":"Statins and cancer: a meta-analysis of case\u2013control studies","volume":"17","author":"Taylor","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0040","first-page":"573","article-title":"Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort","volume":"109","author":"Jacobs","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1874288200802010009","article-title":"Validity and reproducibility of a semi-quantitative food frequency questionnaire adapted to an Israeli population","volume":"2","author":"Yizhaki","year":"2008","journal-title":"Open Nutr J"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10552-008-9139-4","article-title":"Statin use and prostate cancer risk in a large population based setting","volume":"19","author":"Boudreau","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10552-008-9271-1","article-title":"Statin use and female reproductive organ cancer risk in a large population-based setting","volume":"20","author":"Yu","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pds.1507","article-title":"Screening statins for possible carcinogenic risk: up to 9years of follow-up of 361,859 recipients","volume":"17","author":"Friedman","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.20758","article-title":"Cancer risk among statin users: a population-based cohort study","volume":"114","author":"Friis","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.ede.0000254694.03027.a1","article-title":"Statin use and the risk of 10 cancers","volume":"18","author":"Coogan","year":"2007","journal-title":"Epidemiology"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0080","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bjc.6601566","article-title":"Statin use and cancer risk in the General Practice Research Database","volume":"90","author":"Kaye","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0085","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1001\/archinte.160.15.2363","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case\u2013control study","volume":"160","author":"Blais","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0090","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/0008-5472.CAN-10-2953","article-title":"Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort","volume":"71","author":"Jacobs","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0095","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1158\/1940-6207.CAPR-10-0007","article-title":"Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer","volume":"3","author":"Lipkin","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.ygyno.2013.05.025_bb0100","first-page":"1763","article-title":"Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors","volume":"71","author":"Kwan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0105","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/djr291","article-title":"Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study","volume":"103","author":"Ahern","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2008.06.007","article-title":"Impact of statin therapy on survival in epithelial ovarian cancer","volume":"111","author":"Elmore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0115","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/bcr2820","article-title":"Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen","volume":"13","author":"Brennan","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2407-10-103","article-title":"Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance","volume":"10","author":"Martirosyan","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2013.05.025_bb0125","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1349-7006.2008.00977.x","article-title":"Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer","volume":"99","author":"Horiuchi","year":"2008","journal-title":"Cancer Sci"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T15:27:40Z","timestamp":1539617260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813007580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0090825813007580"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of statins on risk and survival of gynecological malignancies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}